Free Trial
NASDAQ:ANIK

Anika Therapeutics Q1 2025 Earnings Report

Anika Therapeutics logo
$14.53 -0.16 (-1.09%)
As of 04:00 PM Eastern

Anika Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
$0.09
Beat/Miss
N/A
One Year Ago EPS
N/A

Anika Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$27.50 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Anika Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Friday, May 9, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Anika Therapeutics Earnings Headlines

Elon Musk’s next move from the Oval Office?
No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Trump himself said Musk was a "once-in-a-generation industry leader." The president has put him to work as an efficiency czar through the newly created DOGE.
See More Anika Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anika Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anika Therapeutics and other key companies, straight to your email.

About Anika Therapeutics

Anika Therapeutics (NASDAQ:ANIK), a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

View Anika Therapeutics Profile

More Earnings Resources from MarketBeat